65 Participants Needed

Lecanemab for Alzheimer's Disease

(DIAN-TU Trial)

Recruiting at 7 trial locations
EZ
JB
JB
SB
Overseen BySarah Berman
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Washington University School of Medicine
Must be taking: Anti-amyloid therapy
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on full anticoagulation or high-dose antiplatelet therapy, you may not be eligible to participate.

What is known about the safety of lecanemab for Alzheimer's disease?

Lecanemab has been studied for safety in people with early Alzheimer's disease. Some side effects include amyloid-related imaging abnormalities (ARIA), which are usually not serious but can be in rare cases, and infusion reactions. People taking blood thinners may have a higher risk of bleeding, and those with a specific gene (APOE4) may have a higher risk of ARIA.12345

What data supports the effectiveness of the drug lecanemab for Alzheimer's disease?

Research shows that lecanemab helps clear amyloid-β (a protein linked to Alzheimer's) from the brain and slows down the worsening of memory and thinking skills in people with early Alzheimer's disease.12346

Who Is on the Research Team?

RJ

Randall J Bateman, MD

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

This trial is for individuals with a genetic form of Alzheimer's disease (DIAD) who were previously part of the DIAN-TU-001 study. Participants must carry specific mutations linked to early-onset Alzheimer's and are willing to undergo treatment with lecanemab.

Inclusion Criteria

My veins are suitable for receiving medication and monitoring.
Previously participated in the DIAN-TU-001 gantenerumab OLE period
Co-enrollment in the DIAN Observational Study (DIAN Obs, NCT00869817) and willing to complete DIAN Obs procedures and assessments
See 3 more

Exclusion Criteria

I have seizures that are not controlled by medication.
I do not have any other active cancers that could affect this study.
More than 20 ARIA-H MCH
See 13 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive open-label lecanemab administered intravenously approximately every 2 weeks

Minimum of 5 years
Bi-weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 year
Annual assessments

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • lecanemab
Trial Overview The study tests if lecanemab can remove amyloid plaques in the brain, which are associated with Alzheimer's, and examines its impact on delaying symptoms onset and slowing down disease progression compared to those not receiving it.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: lecanemabExperimental Treatment1 Intervention
Starting at Week 0, participants will receive open-label lecanemab administered intravenously approximately every 2 weeks for a minimum of 5 years utilizing a common close design.

lecanemab is already approved in United States, China for the following indications:

🇺🇸
Approved in United States as Leqembi for:
  • Alzheimer's disease in the earliest symptomatic stages
🇨🇳
Approved in China as 乐意保 (LEQEMBI) for:
  • Mild cognitive impairment due to Alzheimer’s disease and mild AD dementia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

Alzheimer's Association

Collaborator

Trials
103
Recruited
44,300+

Eisai Inc.

Industry Sponsor

Trials
524
Recruited
161,000+
Founded
Eisai Inc. was established in 1995 as the U.S. subsidiary of Eisai Co., Ltd.
Headquarters
Woodcliff Lake, NJ, USA
Known For
Neurology and Oncology
Top Products
Aricept (donepezil), Lenvima (lenvatinib), Leqembi (lecanemab), Halaven (eribulin)
Lynn Kramer profile image

Lynn Kramer

Eisai Inc.

Chief Medical Officer since 2019

MD

Tatsuyuki Yasuno profile image

Tatsuyuki Yasuno

Eisai Inc.

Chief Executive Officer since 2023

MBA from Kellogg School of Management, Northwestern University; Bachelor of Political Science from Waseda University

Published Research Related to This Trial

Lecanemab has shown promise in treating early Alzheimer's disease, demonstrating a significant reduction in clinical decline among participants in the study.
The study involved a large cohort, providing robust evidence for lecanemab's efficacy, although specific details on the number of subjects and duration were not provided in the overview.
Evidence for lecanemab in early Alzheimer's disease.[2023]
Lecanemab, an IgG1 antibody targeting amyloid-β, received its first approval for treating Alzheimer's disease in the USA on January 6, 2023, specifically for patients with mild cognitive impairment or mild dementia who have confirmed amyloid beta pathology.
The safety and effectiveness of lecanemab have only been established for the specific patient population studied in clinical trials, and there is no data on its use in earlier or later stages of Alzheimer's disease.
Lecanemab: First Approval.Hoy, SM.[2023]
In an 18-month double-blind randomized placebo-controlled trial, lecanemab was effective in clearing amyloid-β in two-thirds of participants with mild cognitive impairment and mild dementia due to Alzheimer's disease.
Lecanemab also significantly reduced the rate of cognitive and functional decline in these individuals, suggesting its potential as a therapeutic intervention for early Alzheimer's disease.
Lecanemab reduces brain amyloid-β and delays cognitive worsening.Knopman, DS.[2023]

Citations

Evidence for lecanemab in early Alzheimer's disease. [2023]
Lecanemab: First Approval. [2023]
Lecanemab reduces brain amyloid-β and delays cognitive worsening. [2023]
Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease. [2023]
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. [2023]
Lecanemab: Appropriate Use Recommendations. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security